<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41914">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01977924</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00763-42</org_study_id>
    <nct_id>NCT01977924</nct_id>
  </id_info>
  <brief_title>Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea</brief_title>
  <acronym>PolySAS</acronym>
  <official_title>Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe obstructive sleep apnea (OSA) is associated with increased cardiovascular morbidity
      and mortality. Endothelial dysfunction, an early marker of vascular disease has been
      demonstrated in OSA. Regular treatment of OSA by continuous positive airway pressure (CPAP)
      improves endothelial function and is associated with a reduction in cardiovascular risk.
      Approximately 40% of patients with OSA are intolerant or insufficiently adherent to CPAP.
      Alternative treatments or adjuvants to the CPAP are needed.

      The polyphenols have demonstrated their effectiveness in improving endothelial function in
      patients with CV disease. No randomized controlled studies have evaluated the impact of PPR
      on the endothelial dysfunction associated with OSAHS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The endpoint is the change to one month of polyphenols treatment of the endothelial function
      measured by the index of hyperemic reactivity.

      The secondary endpoints are changes at one month of supplementation with polyphenols of
      ambulatory blood pressure measurement in 24 hours (MAPA), micro-circulatory responsiveness,
      the speed of the pulse wave and biological measurements (lipid profile, blood glucose,
      fasting insulin, leptin, adiponectin, hs-CRP, 8-isoprostane levels and cellular origin of
      microparticles).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>endothelial function measured by the index of hyperemic reactivity</measure>
    <time_frame>one month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>polyphenols</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg polyphenols (grape extract)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>microcrystalline cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>one month polyphenols supplementation (600mg)</intervention_name>
    <arm_group_label>polyphenols</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo (microcrystalline cellulose)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:•

          -  apnea hypopnea index &gt; 30

          -  accepting polyphenols supplementation

          -  Signed informed consent

        Exclusion Criteria:

          -  Epworth sleepiness scale &gt; 16/24

          -  Severe cardiac and/or respiratory disease

          -  BMI&gt;35 kg/m2

          -  Anemia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wojciech trzepizur, MD</last_name>
    <phone>+33(0) 214353695</phone>
    <email>wotrzepizur@chu-angers.fr</email>
  </overall_contact>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>October 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep apnea</keyword>
  <keyword>polyphenols</keyword>
  <keyword>endothelial function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
